Celadon Pharmaceuticals is set to delist from London's AIM after its directors resigned. The medical cannabis firm on Monday said that it will propose to move ahead with the cancellation of ...

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the ...